Skip to main content
TLSA
NASDAQ Life Sciences

Tiziana Sets Nov 9 KOL Call, Quantifies INFORM-MS Wins (p=0.0168)

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.625
Mkt Cap
$80.18M
52W Low
$0.567
52W High
$1.9
52W Position info
10% above low
Off High info
67% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

TLSA is trading near its 52-week low of $0.567 (10% above the low).

Summary

Tiziana scheduled a November 9 KOL call and put hard numbers on its INFORM-MS win: p=0.0168 on the 50μg TSPO PET endpoint and significant fatigue improvements in both dose arms. The data support a pivotal trial, which the company must now fund against a thin cash position.


Key Events · Product Development and Regulatory · TLSA

  • KOL Call Set for November 9

    Management will host a webcast at 12:00pm ET / 17:00pm GMT with Drs. Tanuja Chitnis, Tarun Singhal and Howard Weiner to review the INFORM-MS dual primary endpoint results and secondary findings.

  • Primary Endpoint p=0.0168 at 50μg

    The 50μg nasal foralumab arm showed a statistically significant reduction in microglial activation on [18F]PBR06 TSPO PET versus placebo; the 100μg arm was exploratory and showed variance in PET outcomes.

  • Fatigue Scores Improve in Both Arms

    MFIS total score fell 6.17 points in the 50μg arm (p=0.035) and 7.18 points in the 100μg arm (p=0.040) after 12 weeks, versus a 3.12-point drop on placebo.

  • Clean Safety Across 48 Patients

    All 48 participants completed treatment with no study-drug related serious adverse events, supporting the non-invasive anti-CD3 profile.


Analysis · TLSA · Life Sciences

This filing adds detail to the 2026-11-02 topline release: the 50μg arm's TSPO PET reduction reached p=0.0168, and fatigue scores fell 6.17 points (p=0.035) and 7.18 points (p=0.040) in the two dose arms versus 3.12 points on placebo. All 48 patients completed with no drug-related serious adverse events. The numbers matter because they are the package Tiziana will take to the FDA for a pivotal trial design, and because the company reported only $3.9M of cash with going-concern doubt on 2026-10-16 — positive, well-quantified data is the main lever for financing that pivotal program. The November 9 call is where investigators explain the dose-response variance between 50μg and 100μg.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLSA was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.2M. The 52-week trading range was $0.57 to $1.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLSA - Latest Insights

TLSA
Nov 02, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.890
Real-time Price: $0.6266 info
Change: -$0.2634 (-30%) info
Market Cap: $80.058M info
TLSA
Nov 02, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.8685
Real-time Price: $0.6266 info
Change: -$0.2419 (-28%) info
Market Cap: $80.058M info
TLSA
Oct 16, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.6266 info
Change: -$0.4234 (-40%) info
Market Cap: $80.058M info
TLSA
Oct 16, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.6266 info
Change: -$0.4434 (-41%) info
Market Cap: $80.058M info
TLSA
Sep 30, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.6266 info
Change: -$0.3734 (-37%) info
Market Cap: $80.058M info